News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PsiOxus Therapeutics Limited To Release Study Results Of Oncolytic Vaccine Enadenotucirev In Cancer Patients


5/13/2014 8:44:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that two of its on-going phase I studies of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting to be held 30 May to 3 June, 2014 in Chicago, Illinois.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES